Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study

Overview of attention for article published in Orphanet Journal of Rare Diseases, July 2018

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

policy: 1 policy source

twitter: 4 X users

Readers on

mendeley: 46 Mendeley

Summary Policy documents X

So far, Altmetric has seen 1 policy document that references this research output.

pegvaliase

Cited by Canadian Agency for Drugs and Technologies in Health on 14 Feb 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.